If a doctor ever told you hormone therapy was a last resort for menopause symptoms, the largest US group of ob-gyns has now updated its advice. The American College of Obstetricians and Gynecologists (ACOG) published a new guideline in October 2026 that replaces its 2014 bulletin on the topic.[1][2] Here is what it covers, what it does not settle, and what to bring to your next appointment.
The short version
- What it is. ACOG Clinical Practice Guideline No. 13, on hot flashes, sleep problems and mood symptoms related to menopause. It replaces Practice Bulletin 141 from January 2014.[2]
- Hormone therapy. The decision should rest on shared decision-making between you and your clinician. When it is chosen, ACOG recommends starting before age 60 or within 10 years of the start of spontaneous menopause, in people without contraindications.[3]
- Other options. The guideline also covers non-hormone medicines, some non-drug approaches, and a warning about herbal products.[3]
- The catch. It is written for clinicians. It does not tell any one person what to take.
What ACOG published
The guideline is titled Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms and appears in the November 2026 issue of Obstetrics & Gynecology.[1] ACOG says it was informed by a systematic review of the evidence, with recommendations rated by strength and evidence quality.[2] It covers people with symptoms from natural menopause or from induced menopause (after surgery, chemotherapy or radiation) at or beyond age 40.[2]
ACOG cites how common the problem is. By its figures, 50% to 92% of women in menopause report vasomotor symptoms (hot flashes and night sweats), 16% to 66% of women in the US report menopause-related sleep disruption, and more than a third of perimenopausal and postmenopausal women worldwide report depressive symptoms.[3]
What it says about hormone therapy
The guideline gives more detail than the old bulletin on the different forms of menopausal hormone therapy and on timing. ACOG recommends that starting treatment be based on shared decision-making, weighing your symptoms, your age, your medical history, your baseline risk of heart disease, breast cancer and blood clots, and your own goals.[3] Decisions about when and how to stop should also be individual, based on ongoing risk assessment and a conversation with your clinician.[3]
The timing advice (before 60, or within 10 years of the start of spontaneous menopause) echoes what researchers have called the timing hypothesis, which stays debated. Hormone therapy has a long, contested history that began with the Women’s Health Initiative results in 2002. This post does not re-litigate that evidence. The summary I read says nothing about what ACOG advises for people outside the timing window, so that is a question for your clinician.
Options beyond hormones
- Neurokinin receptor antagonists (fezolinetant and elinzanetant). ACOG describes these as a new approach to hot flashes, and an option for people who cannot or prefer not to use hormones.[3]
- SSRIs and SNRIs. These antidepressant classes can help with hot flashes and with depression, in people who have one or both.[3]
- Non-drug approaches. The guideline includes cognitive behavioral therapy, mindfulness-based interventions, exercise, clinical hypnosis and acupuncture, usually as add-ons to medication rather than replacements.[3]
- Supplements. ACOG says the evidence does not support the safety or effectiveness of phytoestrogens or herbal supplements for hot flashes or other menopause symptoms, and notes they are not FDA-regulated or tested for purity.[3]
What this does not settle
- I read the journal citation, ACOG’s guideline page and its press release. I did not read the full text, so the grade given to each recommendation is not reported here.
- News coverage may say hormone therapy is now “first-line.” Check the full guideline for the exact wording and strength before repeating that.
- Guidance for genitourinary symptoms (vaginal dryness, urinary changes) is not in this guideline. ACOG says a separate guideline is planned for 2027.[3]
- A guideline sets a standard for clinicians. It does not replace a decision made with someone who knows your history.
What to do with this
Before your visit, track two weeks of hot flashes, night sweats, sleep and mood in your phone. Write down any personal or family history of blood clots, stroke, heart disease or breast cancer, and list every medicine and supplement you take. Then ask your clinician whether hormone therapy, a non-hormone medicine, or a non-drug option fits your situation, and when to revisit the choice. Do not start, stop or change a medication on your own. For help framing that conversation, see How to Actually Talk to Your Doctor About Severe Menopause Symptoms.
References
The guideline abstract was read through ACOG’s guideline page and the CrossRef record. The press release was read as published. The full journal text was not accessed.
[1] American College of Obstetricians & Gynecologists’ Committee on Clinical Practice Guidelines–Gynecology. ACOG Clinical Practice Guideline: Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms. Obstetrics & Gynecology. 2026;148(5):e345-e369. DOI: 10.1097/AOG.0000000000006428. Finding as used: the guideline exists, was published in the November 2026 issue, and addresses vasomotor, sleep and mood symptoms. ↑︎ a b
[2] American College of Obstetricians & Gynecologists. Clinical Practice Guideline No. 13: Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms (November 2026). acog.org guideline page. Finding as used: replaces Practice Bulletin 141 (January 2014); purpose and target population; recommendations classified by strength and evidence quality. ↑︎ a b c d
[3] American College of Obstetricians & Gynecologists. ACOG Expands Recommendations for Management of Menopause Symptoms. Press release, October 15, 2026. acog.org press release. Finding as used: prevalence figures, shared decision-making, initiation before age 60 or within 10 years of spontaneous menopause, individualized discontinuation, nonhormonal and nonpharmacologic options, supplement statement, 2027 genitourinary guidance. ↑︎ a b c d e f g h i j

Kurt Greiner
Kurt is a digital strategist and IT professional blending emerging technology with practical application, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.

Leave a Reply